- Summits
- Sponsorship
- Retreats
- Media Opportunities
- News
- About
Paris-based AI diagnostics company Waiv has secured $33 million in financing to accelerate the global deployment of its AI precision testing platform, marking a new chapter following its spin-out from Owkin, where the team previously operated as Owkin Dx.
The funding round was co-led by OTB Ventures and Alpha Intelligence Capital, with participation from Serena Data Ventures, Karista, and SistaFund. The capital will support Waiv’s efforts to expand its portfolio of AI-enabled precision tests, strengthen pharmaceutical collaborations, and extend access to its platform across international healthcare markets.
Cancer treatment has entered a period of increasing biological complexity. Decisions are no longer guided by a single biomarker but by a combination of biological signals, clinical data, and patient-specific factors. As a result, many healthcare systems are seeking faster and more scalable ways to identify which therapies are most likely to benefit individual patients.
Meriem Sefta, CEO and Co-Founder of Waiv, said:
“Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them. This remains very complex to achieve. Waiv brings the scalability and speed of AI to oncology testing, while enabling drug developers to access insights that were previously out of reach. Our goal is to make accurate AI-enabled precision testing the global standard.”
Waiv is developing diagnostic infrastructure designed specifically for the next generation of precision oncology. Its platform converts digital histopathology images and multimodal clinical data into clinically validated AI-driven tests, revealing biological insights that may not be visible through traditional diagnostics.
The company’s tools are already being used in clinical environments through solutions such as RlapsRisk BC, MSIntuit Suite, and BRCAura, which help laboratories, clinicians, and pharmaceutical developers identify biomarkers and predict treatment responses in minutes. These tools aim to improve testing accuracy, streamline diagnostic workflows, and broaden access to precision medicine by using data already generated during routine care.
Waiv’s technology foundation includes large-scale multimodal datasets, proprietary AI models, and a growing data network built through initiatives such as the PortrAIt consortium, which supports multi-institutional collaboration and strengthens model performance across diverse populations.
The company also operates Destra, an interoperable digital pathology platform that enables laboratories and pathologists to run Waiv’s tests directly within their existing workflows.
Investors backing the round believe the company’s technology addresses a major gap in oncology diagnostics.
Karol Szubstarski, Partner at OTB Ventures, commented:
“Waiv is bringing a level of technological advancement and maturity that oncology has been waiting for. Their AI tech stack, built on advanced foundation models, can convert routine pathology slides into high-resolution maps of disease biology, providing both generalisability and scalability across different clinical settings. We are excited to partner with a world-class team and support Waiv as they set a new standard for how oncology is understood and treated.”
Arnaud Barthélémy, Partner at Alpha Intelligence Capital, added:
“What sets Waiv apart is not just its technology, but its proven clinical impact across applications from outcome prediction to biomarker detection. With exceptional scientific depth, a track record of real-world impact, and strong revenue-generating partnerships with global pharma, Waiv exemplifies how AI is set to revolutionise healthcare – driving highly personalised, efficient, and outcome-focused medicine. As a leader in AI investment since 2018, AIC is committed to supporting this essential movement for the benefit of patients.”
Waiv is also collaborating with research institutions and pharmaceutical companies to develop AI-driven biomarker discovery and clinical trial tools. Among these initiatives are an AI-based gBRCA pre-screen test for breast cancer derived from H&E pathology slides and a collaboration with MSD to identify microsatellite instability (MSI)–enriched patient populations.
With the new funding, Waiv plans to broaden its portfolio of clinical-grade multimodal tests and strengthen its presence across global healthcare systems. The company also aims to deepen integrations with pharmaceutical R&D pipelines, supporting drug development and trial design through AI-guided insights.
As precision oncology continues to evolve, Waiv’s approach reflects a wider shift toward AI-enabled diagnostics that can analyse complex datasets quickly and translate them into practical clinical insights for physicians and patients alike.
Following the success of its Middle East flagship event, MedTech World is now heading to Florida for MedTech World North America, taking place in West Palm Beach from 11 to 13 May 2026.
The North America edition will convene global industry leaders, investors, and innovators for focused discussions, curated networking, and cross-border collaboration opportunities. If you are looking to be part of this milestone flagship event, you can engage in ways that align with your goals:
